(Q45372583)

13 December 2017

Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder (English)

1 reference

13 December 2017

1

R H Perlis

1 reference

13 December 2017

B Fijal

2

1 reference

13 December 2017

S Dharia

series ordinal

3

1 reference

13 December 2017

J P Houston

series ordinal

4

1 reference

13 December 2017

17 January 2012

1 reference

The Pharmacogenomics Journal

13 December 2017

1 reference

13 December 2017

13

1 reference

13 December 2017

280-285

1 reference

13 December 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1038/tpj.2011.62

13 December 2017

0 references

cites work

Anxiety disorders and major depression, together or apart

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.62

The role of pharmacogenetics in the treatment of depression and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.62

Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.62

Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.62

Elevated cortisol in older adults with generalized anxiety disorder is reduced by treatment: a placebo-controlled evaluation of escitalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.62

Genetic predictors of response to antidepressants in the GENDEP project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.62

A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.62

Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.62

Generalized anxiety disorder and major depressive disorder comorbidity: an example of genetic pleiotropy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.62

Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.62

Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.62

Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.62

PLINK: a tool set for whole-genome association and population-based linkage analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.62

Risk and resilience: genetic and environmental influences on development of the stress response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.62

Interaction of childhood maltreatment with the corticotropin-releasing hormone receptor gene: effects on hypothalamic-pituitary-adrenal axis reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.62

Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.62

Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.62

Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.62

21 January 2018

Identifiers

DOI

10.1038/TPJ.2011.62

1 reference

Dimensions Publication ID

13 December 2017

0 references

1 reference